Technology area: Biotechnology & Pharmaceuticals
7 pending office actions • 6 art units • 7 examiners • 0 of 7 (0%) have an AI response strategy ready • 4 patents granted in the last 365 days
The Queensland Institute of Medical Research has 7 pending office actions in the Biotechnology & Pharmaceuticals technology area. Each of these 7 actions is assigned to a different distinct examiner, resulting in a perfectly distributed workload across the 7 examiners. These matters are also spread across 6 distinct art units, showing that the institute's research spans several specialized biological and pharmaceutical classifications. MATALKAH, FATIMAH KHALAF is identified as the busiest examiner, though they only have 1 pending action.
This reflects the fact that no single examiner is currently handling more than one matter for the institute. The high ratio of 6 art units to 7 pending actions highlights the diverse nature of the institute's intellectual property within the Biotechnology & Pharmaceuticals field. For a practitioner, this means that the 7 pending office actions require managing 7 separate examiner relationships. The 1 pending action under MATALKAH, FATIMAH KHALAF is just one component of a highly fragmented prosecution landscape. This structure requires coordinating across 6 different specialized units.
Based on the USPTO statutory response window for each pending office action. 4 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 4 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 2 (29%) |
| §103 only | 2 (29%) |
| §112 only | 1 (14%) |
| Multi-statute (no §101) | 2 (29%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| MATALKAH, FATIMAH KHALAF | 1 | 55.8% | +27.4% |
| BANERJEE, KOYELI | 1 | 33.3% | +0.0% |
| BOWLES, DAVID PAUL | 1 | 69.6% | +28.1% |
| GILL, RACHEL B | 1 | 65.4% | +28.8% |
| VAN BUREN, LAUREN K | 1 | 40.0% | +58.4% |
| SINGH, ANOOP KUMAR | 1 | 43.2% | +67.7% |
| JOHANNSEN, DIANA B | 1 | 53.2% | +42.8% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 4 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17913937 | COMPOSITIONS AND METHODS FOR TARGETING HPV-INFECTED CELLS | SINGH, ANOOP KUMAR | 26d |
| 17274126 | BIOMARKERS FOR CANCER THERAPY | JOHANNSEN, DIANA B | 33d |
| 18287793 | NOVEL COMPOSITIONS AND METHODS FOR TREATING CORONAVIRUS INFECTIONS | BANERJEE, KOYELI | — |
| 17926106 | IMMUNE CELLS WITH ENHANCED FUNCTION | VAN BUREN, LAUREN K | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 6 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18273200 | NOVEL BICYCLIC PEPTIDES | BOWLES, DAVID PAUL | 25d overdue |
| 17913937 | COMPOSITIONS AND METHODS FOR TARGETING HPV-INFECTED CELLS | SINGH, ANOOP KUMAR | 26d |
| 17274126 | BIOMARKERS FOR CANCER THERAPY | JOHANNSEN, DIANA B | 33d |
| 18030892 | HERPESVIRUS POLYEPITOPE VACCINES | GILL, RACHEL B | 34d |
| 18996968 | ENGINEERED HUMAN CARDIAC TISSUE | MATALKAH, FATIMAH KHALAF | — |
| 17926106 | IMMUNE CELLS WITH ENHANCED FUNCTION | VAN BUREN, LAUREN K | — |
| Art Unit | Apps |
|---|---|
| 1638 | 2 |
| 1658 | 1 |
| 1654 | 1 |
| 1671 | 1 |
| 1632 | 1 |
| 1682 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18996968 | ENGINEERED HUMAN CARDIAC TISSUE | MATALKAH, FATIMAH KHALAF | 1638 | §103 | Non-Final OA | — | Pending | Jan 17, 2025 |
| 18287793 | NOVEL COMPOSITIONS AND METHODS FOR TREATING CORONAVIRUS INFECTIONS | BANERJEE, KOYELI | 1658 | §101§102§103§112 | Non-Final OA | — | Pending | Oct 20, 2023 |
| 18273200 | NOVEL BICYCLIC PEPTIDES | BOWLES, DAVID PAUL | 1654 | §112 | Non-Final OA | 25d overdue | Pending | Jul 19, 2023 |
| 18030892 | HERPESVIRUS POLYEPITOPE VACCINES | GILL, RACHEL B | 1671 | §103Other | Final Rejection | 34d | Pending | Apr 07, 2023 |
| 17926106 | IMMUNE CELLS WITH ENHANCED FUNCTION | VAN BUREN, LAUREN K | 1638 | §102§103 | Non-Final OA | — | Pending | Nov 17, 2022 |
| 17913937 | COMPOSITIONS AND METHODS FOR TARGETING HPV-INFECTED CELLS | SINGH, ANOOP KUMAR | 1632 | §102§112 | Final Rejection | 26d | Pending | Sep 23, 2022 |
| 17274126 | BIOMARKERS FOR CANCER THERAPY | JOHANNSEN, DIANA B | 1682 | §101§103§112 | Final Rejection | 33d | Pending | Mar 05, 2021 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialThe Queensland Institute of Medical Research has 7 pending office actions as of October 2026, spread across 6 art units and 7 examiners.
Fatimah Khalaf Matalkah has the most, with 1 of The Queensland Institute of Medical Research's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
